Literatur
-
1
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, vanOsteroom A T.
Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
Eur J Cancer.
2004;
40
689-695
-
2
Chen C J, Trent J C, Wu E F, Fuller G N, Ramdas L, Zhang W, Raymond A K, Prieto V G, Oyedeji C O, Hunt K K, Pollock R E, Feig B W, Hayes K J, Choi H, Macapinlac H A, Hittelman W, Valesco M A, Patel S, Burgess M A, Benjamin R S, Frazier M L.
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Cancer Res.
2004;
64
5913-5919
-
3
Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K.
Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
Br J Cancer.
2004;
90
2059-2061
-
4
Tamborini E, Bonadiman I, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Collechia M, Casali P G, Pierotti M A, Pilotti S.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Gastroenterology.
2004;
127
294-299
-
5
Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, van Osteroom A, Marynen P.
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against Imatinib-resistant mutants.
Gastroenterology.
2005;
128
270-279
-
6
Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner C C, Heinicke T, Hohenberger P.
Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations.
Lancet Oncology.
2005;
6
249-251
-
7
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour J F, Arthur C, Joske D, Lynch K, Hughes T.
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood.
2003;
102
276-283
PD Dr. med. Eva Wardelmann
Institut für Pathologie, Universitätsklinikum Bonn
Sigmund-Freud-Straße 25 · 53127 Bonn
Email: eva.wardelmann@ukb.uni-bonn.de
